Skip to main content
. 2022 Feb 11;12:843299. doi: 10.3389/fonc.2022.843299

Table 3.

Kinase inhibition activity of diverse EGFR TKIs against p.L747P and EGFR WT cell lines.

Compounds IC50 (nmol) A431 WT A431 p.L747P
Gefitinib 724.8 147.3
Erlotinib 945.1 167.3
Afatinib 14.5 6.7
Dacomitinib 13.1 5.2
Osimertinib 341.6 80.9
Poziotinib 1.1 1.6
Mobocertinib 17.2 15.8